Oral ganciclovir in the prevention of cytomegalovirus infection in postkidney transplant "CMV at risk" recipients: a controlled, comparative study of two regimens (750 mg Bid and 500 mg Bid).
Ahsan
N
N
Department of Medicine and Section of Transplantation, Milton S. Hershey Medical Center, Pennsylvania State University, Hershey 17033, USA.
Holman
M J
MJ
Sonderbye
L
L
Langhoff
E
E
Yang
H C
HC
D000284:Administration, Oral; D000998:Antiviral Agents / Q000627:therapeutic use*; D003586:Cytomegalovirus Infections / Q000453:epidemiology / Q000517:prevention & control*; D004305:Dose-Response Relationship, Drug; D005260:Female; D005500:Follow-Up Studies; D015774:Ganciclovir / Q000627:therapeutic use*; D006801:Humans; D007676:Kidney Failure, Chronic / Q000209:etiology / Q000601:surgery; D016030:Kidney Transplantation; D008297:Male; D008875:Middle Aged; D010865:Pilot Projects; D011183:Postoperative Complications; D011446:Prospective Studies; D012307:Risk Factors
D000998:Antiviral Agents; D015774:Ganciclovir